Co-Diagnostics Posts $1.46 Q2 Loss Per Share
CODX sits 18% above its 52-week low of $1.26 on light trading volume (0.1× avg).
Summary
Co-Diagnostics reported a Q2 loss of $1.46 per share, a significant figure relative to its $1.49 stock price. The company has been burning cash and raising capital through deeply discounted placements and an ATM program, with a going concern warning already on file. This loss adds to the financial strain and likely pressures the stock further. Watch for any commentary on cash runway or additional financing needs in the full earnings release.
Updates
· SEC 10-Q — Cash and cash equivalents fell to $3.6 million at June 30, 2026 from $11.9 million at December 31, 2025. The 10-Q states substantial doubt exists about the company's ability to continue as a going concern.
At the time of this announcement, CODX was trading at $1.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $1.26 to $46.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.